Comparison
LL-37 vs. Sincalide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
597562-32-8
25126-32-3
Molecular weight
4493.33 g/mol
1143.29 g/mol
Half-life
no data
no data
Sequence
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESAsp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2Mechanism of action
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Sincalide
Sincalide activates CCK receptors, triggering gallbladder contraction and pancreatic enzyme secretion. This effect is used diagnostically to measure the gallbladder ejection fraction (e.g. in HIDA scintigraphy).
Evidence base
Highest evidence
Human trial
Human trial
Studies
4
0
of which in humans
1
0
Effects recorded
4
1
Open conflicts
1
0
Documented adverse events
0
1
Legal status
Full entries
Frequently asked questions
- What is the difference between LL-37 and Sincalide?
- LL-37 is classified as "Research other", while Sincalide is classified as "Research other". LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. Sincalide: Sincalide is the synthetic C-terminal octapeptide of the hormone cholecystokinin (CCK-8). As Kinevac it is FDA-approved to stimulate gallbladder contraction for diagnostic imaging. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, LL-37 or Sincalide?
- The highest available evidence level is "Human trial" for LL-37 and "Human trial" for Sincalide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of LL-37 and Sincalide in Germany and the United States?
- Germany: LL-37 — Research only, Sincalide — Unclear. United States: LL-37 — Research only, Sincalide — Prescription. These are factual summaries with source and review date on the individual pages.